Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus (NASDAQ: EOLS) reported Q4 2025 revenue of $90.3M and full‑year 2025 revenue of $297.2M, representing 14% and 12% growth respectively, its sixth consecutive year of double‑digit growth. The company achieved GAAP operating income of $4.2M in Q4 and ended 2025 with $53.8M cash.
Management provided 2026 guidance of $327M–$337M revenue (10%–13% growth), non‑GAAP operating expense of $210M–$216M (0%–3% growth), and expects a low‑ to mid‑single digit adjusted EBITDA margin in 2026, while forecasting $450M–$500M revenue and 13%–15% adjusted EBITDA margins in 2028.
Evolus (NASDAQ: EOLS) said its management team will participate in a fireside chat and investor meetings at the Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, 2026 at 11:20 AM ET. The webcast will be available on the company Investor Relations page and a replay will be posted for 90 days.
Evolus (NASDAQ: EOLS) will report fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026 after U.S. market close. Management will host a conference call and live webcast at 4:30 p.m. ET the same day, followed by Q&A.
Dial-in numbers, webcast links, telephonic replay details, and an archived webcast will be available on the company's Investor Relations website.
Evolus (NASDAQ: EOLS) announced inducement equity grants to 36 newly hired non-executive employees comprising 153,218 restricted stock units and 34,952 stock options granted between December 7, 2025 and February 7, 2026.
The awards were approved under the 2023 Inducement Incentive Plan, vest 25% annually, and options carry an exercise price equal to the closing price on the last business day before each grant date.
Evolus (NASDAQ: EOLS) reported preliminary unaudited net revenue of $88.6M–$90.6M for Q4 2025 (up 12%–15% YoY) and $295.5M–$297.5M for full-year 2025 (up 11%–12% YoY). The company reaffirmed Q4 2025 non-GAAP operating income of $5M–$7M and provided 2026 net revenue guidance of $327M–$337M (11%–13% growth vs. preliminary 2025). Evolysse and Estyme injectable HA gels are expected to contribute 10%–12% of 2026 revenue. Cash and equivalents were $53M as of Dec 31, 2025. Long-term outlook updated to $450M–$500M revenue for 2028 with 13%–15% non-GAAP operating margins.
Evolus (NASDAQ: EOLS) announced inducement equity grants approved under the Evolus 2023 Inducement Incentive Plan with a grant and vesting commencement date of November 7, 2025.
The company granted non-qualified stock options to purchase an aggregate of 17,871 shares and 45,063 restricted stock units (RSUs) to 13 newly hired non-executive employees. The stock options carry an exercise price of $6.56 (closing price on November 7, 2025), a 10-year term, and vest over 4 years with 25% vesting each annual anniversary. RSUs vest 25% on each annual anniversary.
All awards are subject to the plan and to individual award agreements, including continuous employment vesting conditions, and were approved as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Evolus (NASDAQ: EOLS) reported Q3 2025 total net revenue of $69.0 million, up 13% year-over-year, including $63.2 million in global Jeuveau revenue and $5.7 million from Evolysse. Gross margin was 66.5% (adjusted 67.6%). GAAP operating loss narrowed to $11.5 million; non-GAAP loss from operations was $3.1 million. Cash and cash equivalents were $43.5 million on September 30, 2025 after proactive inventory purchases. The company reaffirmed 2025 revenue guidance of $295–$305 million, non-GAAP OpEx of $208–$213 million, and now expects positive non-GAAP operating income of $5–$7 million in Q4 2025.
Evolus (NASDAQ: EOLS) said members of its management team will participate in a fireside chat and investor meetings at the 2025 Stifel Healthcare Conference. The fireside chat is scheduled for Tuesday, November 11, 2025 at 11:20 AM ET. Investors can access the live webcast on Evolus' Investor Relations page, and a replay will be available for 90 days after the presentation date.
This notice provides event timing, access details, and replay availability for shareholders and market observers.
Evolus (NASDAQ: EOLS) will report its third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. markets close. Management will host a conference call and live webcast at 4:30 p.m. ET the same day, followed by a question-and-answer session.
Investors can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or listen via the live webcast on the Evolus Investor Relations page. A telephonic replay will be available at (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13756397. An archived webcast will be posted at www.evolus.com.
Evolus (NASDAQ: EOLS) announced inducement equity awards for nine newly hired non‑executive employees under its 2023 Inducement Incentive Plan.
The company granted an aggregate of 24,931 non‑qualified stock options and 31,116 restricted stock units (RSUs) with a grant and vesting commencement date of October 7, 2025. The stock options carry a $6.26 exercise price (the closing price on October 7, 2025), a 10‑year term, and vest 25% on each annual anniversary over four years. The RSUs vest 25% on each annual anniversary over four years. Awards were approved by the compensation committee as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to plan and award agreement terms, including continued employment requirements for vesting.